Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
NOTCH1
T-cell acute lymphoblastic leukemia
flow cytometry
measurable (minimal) residual disease
oncogenetics
pediatrics
risk-factors
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
10
2020
accepted:
31
12
2020
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Robust and applicable risk-stratifying genetic factors at diagnosis in pediatric T-cell acute lymphoblastic leukemia (T-ALL) are still lacking, and most protocols rely on measurable residual disease (MRD) assessment. In our study, we aimed to analyze the impact of
Identifiants
pubmed: 33614543
doi: 10.3389/fped.2020.614521
pmc: PMC7892614
doi:
Types de publication
Journal Article
Langues
eng
Pagination
614521Informations de copyright
Copyright © 2021 Vega-García, Perez-Jaume, Esperanza-Cebollada, Vicente-Garcés, Torrebadell, Jiménez-Velasco, Ortega, Llop, Abad, Vagace, Minguela, Pratcorona, Sánchez-Garcia, García-Calderón, Gómez-Casares, Martín-Clavero, Escudero, Riñón Martinez-Gallo, Muñoz, Velasco, García-Morin, Català, Pascual, Velasco, Fernández, Lassaletta, Fuster, Badell, Molinos-Quintana, Molinés, Guerra-García, Pérez-Martínez, García-Abós, Robles Ortiz, Pisa, Adán, Díaz de Heredia, Dapena, Rives, Ramírez-Orellana, Camós and on behalf of the Biological Committee of the Group of Leukaemia of the Spanish Society of Paediatric Haematology Oncology (SEHOP Group).
Déclaration de conflit d'intérêts
MT reports travel and accommodation support from Novartis (outside the submitted work); travel and accommodation support from Jazz Pharma and Shire/Servier (outside the submitted work); and travel and accommodation support from Amgen (outside the submitted work). JLF is a consultant/advisory member for Amgen, Jazz Pharmaceuticals, and Novartis (outside the submitted work), receives honoraria for speaking at symposia from Amgen, Servier, Jazz Pharmaceuticals, and Pfizer (outside the submitted work) and support for attending symposia from Servier and Jazz Pharmaceuticals (outside the submitted work). AM discloses talk fees from Jazz Pharma and Shire/Servier outside the presented work and reports travel and accommodation support from Jazz Pharma, Shire/Servier, and Novartis (outside the submitted work). JD reports advisory board honorarium, speaker fees, and travel and accommodation support from Jazz Pharma and Shire/Servier; personal fees, advisory board honorarium, speaker fees, and travel and accommodation support from Novartis (outside the submitted work); advisory board honorarium, and travel and accommodation support from Amgen (outside the submitted work); advisory board honorarium, speaker fees, and travel and accommodation support from Celgene (outside the submitted work); advisory board honorarium, speaker fees, and travel and accommodation support from Sobi (outside the submitted work). SR reports advisory board honorarium, speaker fees, and travel and accommodation support from Jazz Pharma and Shire/Servier; personal fees, advisory board honorarium, speaker fees, and travel and accommodation support from Novartis (outside the submitted work); advisory board honorarium, and travel and accommodation support from Amgen (outside the submitted work); advisory board honorarium, speaker fees, and travel and accommodation support from Celgene (outside the submitted work). MC discloses talk fees from Shire/Servier outside the presented work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2004 Oct 8;306(5694):269-71
pubmed: 15472075
Blood Adv. 2017 Nov 28;1(25):2456-2466
pubmed: 29296895
Leukemia. 1995 Oct;9(10):1783-6
pubmed: 7564526
Eur J Haematol. 2019 Jan;102(1):79-86
pubmed: 30267597
Haematologica. 2013 Jun;98(6):928-36
pubmed: 23349303
Genes Chromosomes Cancer. 2017 Nov;56(11):810-820
pubmed: 28758283
Leukemia. 2019 Jun;33(6):1324-1336
pubmed: 30552401
Blood. 2011 Aug 25;118(8):2077-84
pubmed: 21719599
N Engl J Med. 2012 Apr 12;366(15):1371-81
pubmed: 22494120
Oncotarget. 2017 Jun 19;8(39):66360-66370
pubmed: 29029518
J Clin Oncol. 2013 Dec 1;31(34):4333-42
pubmed: 24166518
Dis Markers. 2010;28(6):353-60
pubmed: 20683149
Blood. 2009 Apr 23;113(17):3918-24
pubmed: 19109228
Cold Spring Harb Perspect Med. 2020 Mar 2;10(3):
pubmed: 31570389
Leukemia. 2010 Dec;24(12):2023-31
pubmed: 20861920
Blood. 2008 May 1;111(9):4477-89
pubmed: 18285545
Lancet Oncol. 2019 Mar;20(3):e142-e154
pubmed: 30842058
Leukemia. 2019 Sep;33(9):2241-2253
pubmed: 31243313
Haematologica. 2012 Sep;97(9):1405-13
pubmed: 22491738
Blood. 2018 Mar 22;131(12):1350-1359
pubmed: 29284596
Blood. 2017 Mar 2;129(9):1113-1123
pubmed: 28115373
Leukemia. 2012 Sep;26(9):1899-907
pubmed: 22948488
Pediatr Blood Cancer. 2019 Jan;66(1):e27496
pubmed: 30280491
Curr Hematol Malig Rep. 2018 Aug;13(4):265-274
pubmed: 29948644
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Front Oncol. 2020 Apr 24;10:577
pubmed: 32391267
Blood. 2013 Jul 4;122(1):74-82
pubmed: 23687089
Blood. 2008 Oct 15;112(8):3373-82
pubmed: 18663146
Cancer Sci. 2019 Feb;110(2):784-794
pubmed: 30387229
J Clin Oncol. 2008 Jun 20;26(18):3046-50
pubmed: 18565891
Med Clin (Barc). 2012 Jul 7;139(4):141-9
pubmed: 22459573
Nat Rev Cancer. 2016 Jul 25;16(8):494-507
pubmed: 27451956
Leukemia. 2010 Dec;24(12):2014-22
pubmed: 20861909
Oncotarget. 2015 Feb 20;6(5):2754-66
pubmed: 25595890
Br J Haematol. 2009 Apr;145(2):198-206
pubmed: 19245433
Blood. 2009 Dec 10;114(25):5136-45
pubmed: 19828704
Leukemia. 2010 Dec;24(12):2005-13
pubmed: 20944675
Blood. 2020 Jan 16;135(3):159-166
pubmed: 31738819
Leukemia. 2004 Apr;18(4):685-92
pubmed: 14990973
Blood. 2018 Jan 18;131(3):289-300
pubmed: 29051182
Leukemia. 2016 Jan;30(1):39-47
pubmed: 26220040
Ann Hematol. 2015 Nov;94(11):1817-28
pubmed: 26341754
Leukemia. 2013 Jan;27(1):41-7
pubmed: 22814294
Front Oncol. 2019 Apr 30;9:316
pubmed: 31338319
Blood. 2013 Apr 18;121(16):3153-60
pubmed: 23396305
J Hematol Oncol. 2018 Jul 24;11(1):96
pubmed: 30041662
Blood. 2002 Jul 15;100(2):420-6
pubmed: 12091331